Return to search

Identification and characterization of flavin-containing monooxygenase isoform 2 (FMO2) in Rhesus monkey and examination of a human FMO2 polymorphism

Flavin-containing monooxygenase (FMO, EC1.14.13.8) comprises a family of
xenobiotic-metabolizing enzymes that catalyze the oxygenation of a wide variety of
xenobiotics, most commonly nitrogen and sulfur. Mammals express five different FMOs
in a species- and tissue- specific manner. FMO2, is expressed predominantly in lung and
differs from other FMOs in that it can catalyze the N-oxygenation of certain primary
alkylamines. From its initial discovery as an unique form of FMO in lung, FMO2 has been
studied primarily using a rabbit animal model. The initial goal of this research was to
characterize this protein in a primate animal model. To understand FMO2 protein
structure at the molecular level, we first cloned cDNA from a monkey lung cDNA library.
Monkey FMO2 is expressed predominantly in lung. The high expression levels and broad
substrate specificity in monkey, suggests that FMO2 plays a role in xenobiotic metabolism
in this primate model. We then established a heterologous expression system to generate
FMO2 with biological functionality in vitro. FMO2 from baculovirus-mediated expression
resembled monkey and rabbit microsomal FMO2 immunochemically and catalytically. The
successful FMO2 expression in the baculovirus system will serve as a valid tool for
structure studies of protein functional domains, as well as, the amino acids responsible for
enzyme properties of chimeras. Human FMO2 encodes a truncated protein containing
471 amino acid residues, 64 amino acids shorter in its C-terminal than orthologs in other
species. We characterized human FMO2 in terms of gene polymorphism (genotyped by
Dr. Hines), protein levels and catalytic activity with human lung microsomes. An
ethnically related polymorphism was observed, in which all Caucasians genotyped to date
are homozygous for a truncated, enzymatically inactive enzyme which may not even be
translated. Approximately 15% of humans of African descent are heterozygous for full-length
FMO2, but the level of expression may not be sufficient to significantly effect drug
metabolism in the lung. The results of truncated FMO2 produced from baculovirus
expression suggest that the C-terminal of FMO2 might be responsible for enzyme stability
and/or proper structure necessary to exert fully enzyme activity. We conclude that the
human FMO2 possesses unique features compared to all other mammals examined to date
including other primates. / Graduation date: 1999

Identiferoai:union.ndltd.org:ORGSU/oai:ir.library.oregonstate.edu:1957/33434
Date04 January 1999
CreatorsYueh, Mei-Fei
ContributorsWilliams, David E.
Source SetsOregon State University
Languageen_US
Detected LanguageEnglish
TypeThesis/Dissertation

Page generated in 0.0022 seconds